News

Biopharma: M&A activity slows
Enlarge image

BusinessSwitzerlandEU

Biopharma: M&A activity slows

19.11.2012 - Big Pharma has spent less money on M&A this year than in 2011, a new report from Deloitte Recap reveals.

Last year, only US$245bn were spent on acquisitions in the life sciences field, according to the analysts from Deloitte Recap LLC. And this year might even get worse: Only US$142bn were invested in this year’s first nine months. The stream of investments has become a feeble trickle – it’s likely that 2012 will end with another drop in the already low M&A sums. Together with similarly shrinking venture capital investments and reduced milestone payments in licensing deals, this adds up to bleak prospects.

Experts hadn’t expected this development. On the contrary, in the wake of the economic crisis, analysts assumed that the number of deals would rise, even though the single acquisition would cost less. But just the opposite says Deloitte Recap's senior biotech analyst Chris Dokomajilar: The industry would be catching its breath, working through the consolidation period while selectively picking off companies that can be easily bagged and bolted on to a big organisation.

Industry is getting increasingly adverse against taking risks. The kind of biotech looking most appealing to buyers at the moment would be a developer with a Phase II asset that's cleared the proof-of-concept hurdle, says Dokomajilar, where the buyer is looking at a significantly de-risked approach to late-stage trial work. This holds true, if you take a look at the five top dealmakers in licensing and joint venture, compiled by FierceBiotech: While leader Roche/Genentech (total deal volume US$1.37bn) closed deals for products in discovery stage or preclinical testing, runners up Abbott (total deal volume: US$1.37bn) and Merck & Co. (total deal volume: US$1.3bn) focused on products in Phase II and Phase III respectively.

According to Dokomajilar, there are some indicators that the situation might improve in the future: "The past few years brought a tremendous amount of liquidity," Dokomajilar told FierceBiotech, counting US$215b in "committed" dollars, upfront and equity payments offering investors a chance to cash out. Many of those investor groups are required to reinvest a portion of their cash in this industry. This means that a lot of that money should be flowing back in. That, however, still hasn’t happened yet.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/biopharma-ma-activity-slows.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%

TOP

  • NORDIC NANOVECTOR (N)34.50 NOK40.8%
  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • GW PHARMACEUTICALS (UK)514.61 GBP-13.6%
  • WILEX (D)1.46 EUR-13.6%

TOP

  • NICOX (F)10.29 EUR430.4%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK81.6%

FLOP

  • BB BIOTECH (D)44.30 EUR-82.9%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)92.00 GBP-73.1%

No liability assumed, Date: 30.08.2016